Anbio Biotechnology (NNNN) Fundamental Analysis: Revenue, Earnings & Valuation

0.53 / 10

Underperform

Fundamental rating is Underperform. Revenue fell 21.6% YoY, yet gross margin is high at 92.3% and fixed‑asset turnover is strong. Income‑tax ratio is zero, indicating tax concerns. Overall fundamentals remain weak.

Analysis Checks(5/6)

Total operating revenue (YoY growth rate %)

Value-21.63

Score3/3

Weight-153.29%

1M Return1.54%

Inventory turnover ratio

Value37.77

Score2/3

Weight110.65%

1M Return-1.21%

Gross profit margin (%)

Value92.32

Score2/3

Weight-179.45%

1M Return1.69%

Income tax / Total profit (%)

Value0.00

Score1/3

Weight45.39%

1M Return-0.50%

Fixed assets turnover ratio

Value1017.92

Score3/3

Weight-101.39%

1M Return1.06%

Cost of sales ratio (%)

Value7.68

Score2/3

Weight378.08%

1M Return-4.42%

Is NNNN undervalued or overvalued?

NNNN scores 0.53/10 on fundamentals and holds a Premium valuation at present. Backed by its 16.98% ROE, 37.20% net margin, 1445.00 P/E ratio, 135.01 P/B ratio, and 100.92% earnings growth, these metrics solidify its Underperform investment rating.